surovatamig + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone

This is a **combination cancer therapy regimen** composed of six active drugs: **surovatamig** (an investigational CD47-blocking antibody), **rituximab** (an anti-CD20 monoclonal antibody), **cyclophosphamide** (an alkylating chemotherapy agent), **doxorubicin** (an anthracycline chemotherapy agent), **vincristine** (a vinca alkaloid), and **prednisone** (a synthetic glucocorticoid). - **Surovatamig** is being developed as a novel immune checkpoint inhibitor, targeting CD47 to enhance phagocytosis of tumor cells (a "do not eat me" signal inhibitor). - **Rituximab** targets CD20 on B-lymphocytes, inducing antibody-dependent cellular cytotoxicity and complement-mediated cytotoxicity. - **Cyclophosphamide** is a cytotoxic agent causing crosslinking of DNA, thereby inhibiting cell division. - **Doxorubicin** intercalates into DNA and inhibits topoisomerase II, leading to DNA damage and apoptosis. - **Vincristine** disrupts microtubule formation in mitosis. - **Prednisone** acts as an immunosuppressant and induces apoptosis in cancerous lymphocytes. This combination is most likely under investigation for **B-cell non-Hodgkin lymphoma** (such as diffuse large B-cell lymphoma, DLBCL) and potentially other lymphoid malignancies. The addition of surovatamig suggests the regimen aims to improve outcomes over traditional regimens like R-CHOP by augmenting immune-mediated antitumor effects and direct cytotoxicity.